BMO Capital Markets reaffirmed their sell rating on shares of Eli Lilly and Company (NYSE:LLY) in a research report released on Wednesday morning. They currently have a $73.00 target price on the stock.

Several other analysts have also commented on the stock. Berenberg Bank reissued a buy rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. TheStreet raised shares of Eli Lilly and from a c+ rating to a b+ rating in a research note on Tuesday, July 25th. UBS AG lowered shares of Eli Lilly and to a hold rating and set a $85.00 target price for the company. in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an outperform rating to a market perform rating and set a $90.00 target price for the company. in a research note on Wednesday, July 26th. Finally, Leerink Swann lowered shares of Eli Lilly and from an outperform rating to a market perform rating and cut their target price for the company from $93.00 to $90.00 in a research note on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $88.27.

Shares of Eli Lilly and (NYSE:LLY) traded down 3.02% on Wednesday, hitting $78.25. The company had a trading volume of 3,470,423 shares. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72. The stock has a market cap of $82.55 billion, a PE ratio of 33.86 and a beta of 0.34. The company has a 50-day moving average of $82.70 and a 200 day moving average of $81.91.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $0.86 earnings per share. Analysts anticipate that Eli Lilly and will post $4.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Receives “Sell” Rating from BMO Capital Markets” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/17/eli-lilly-and-company-lly-receives-sell-rating-from-bmo-capital-markets.html.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.58%. Eli Lilly and’s payout ratio is 90.04%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 669,733 shares of company stock valued at $55,845,287. Insiders own 0.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC raised its position in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the period. Washington Trust Bank raised its position in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the period. Blair William & Co. IL raised its position in shares of Eli Lilly and by 13.1% in the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock valued at $21,974,000 after buying an additional 30,299 shares during the period. Finally, Bollard Group LLC raised its position in shares of Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the period. Institutional investors own 75.59% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.